ATE454455T1 - Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung - Google Patents
Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellungInfo
- Publication number
- ATE454455T1 ATE454455T1 AT06719694T AT06719694T ATE454455T1 AT E454455 T1 ATE454455 T1 AT E454455T1 AT 06719694 T AT06719694 T AT 06719694T AT 06719694 T AT06719694 T AT 06719694T AT E454455 T1 ATE454455 T1 AT E454455T1
- Authority
- AT
- Austria
- Prior art keywords
- guiding
- production
- heterologous
- polypeptides
- sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64701305P | 2005-01-27 | 2005-01-27 | |
| PCT/US2006/002951 WO2006081430A2 (en) | 2005-01-27 | 2006-01-27 | Leader sequences for directing secretion of polypeptides and methods for production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE454455T1 true ATE454455T1 (de) | 2010-01-15 |
Family
ID=36741080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06719694T ATE454455T1 (de) | 2005-01-27 | 2006-01-27 | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080286834A1 (de) |
| EP (1) | EP1841874B1 (de) |
| JP (2) | JP2008528033A (de) |
| AT (1) | ATE454455T1 (de) |
| AU (1) | AU2006207999A1 (de) |
| CA (1) | CA2589895A1 (de) |
| DE (1) | DE602006011574D1 (de) |
| DK (1) | DK1841874T3 (de) |
| WO (1) | WO2006081430A2 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (de) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Zusammensetzungen und Verfahren zur Behandlung von Krankheiten mit FGFR-Fusionsproteinen |
| DK1937815T3 (en) * | 2005-09-13 | 2015-08-03 | Nat Res Council Canada | Methods and compositions for the modulation of tumor cell activity |
| US9060961B2 (en) * | 2006-11-09 | 2015-06-23 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| WO2009056330A1 (en) * | 2007-10-31 | 2009-05-07 | Eth Zurich | Soluble truncated apom proteins and medical uses thereof |
| CA2719582A1 (en) * | 2008-03-25 | 2009-10-01 | Amarantus Therapeutics, Inc. | Methods and compositions for treating parkinson's disease with manf |
| FR2933773B1 (fr) * | 2008-07-10 | 2013-02-15 | Biomerieux Sa | Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal |
| WO2010017198A2 (en) | 2008-08-04 | 2010-02-11 | Five Prime Therapeutics, Inc. | Fgfr extracellular domain acidic region muteins |
| WO2010075194A1 (en) * | 2008-12-22 | 2010-07-01 | St. Jude Children's Research Hospital | Prokaryotic expression of soluble, active dkk |
| JP2010183885A (ja) * | 2009-02-13 | 2010-08-26 | Kobe Univ | タンパク質の製造方法およびそれに用いる発現ベクター |
| US8445445B2 (en) | 2009-09-15 | 2013-05-21 | Five Prime Therapeutics, Inc. | Method of promoting hair growth using FGFR4 extracellular domains |
| PL2498799T3 (pl) | 2009-11-13 | 2017-03-31 | Five Prime Therapeutics, Inc. | Zastosowanie białek domeny zewnątrzkomórkowej FGFR1 do leczenia nowotworów charakteryzujących się mutacjami aktywującymi zależnymi od ligandów w FGFR2 |
| AU2010324506B2 (en) | 2009-11-24 | 2015-02-26 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| EP2512501A4 (de) | 2009-12-17 | 2014-01-01 | Five Prime Therapeutics Inc | Haarwuchsverfahren unter verwendung extrazellulärer fgfr3-domänen |
| DK2566517T3 (en) | 2010-05-04 | 2019-01-07 | Five Prime Therapeutics Inc | ANTIBODIES THAT BIND CSF1R |
| WO2012006027A1 (en) | 2010-06-28 | 2012-01-12 | Five Prime Therapeutics, Inc. | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same |
| EP2444495A1 (de) * | 2010-10-20 | 2012-04-25 | Algenics | Sekretion rekombinanter Polypeptide im extrazellularen Medium eines Diatoms |
| AU2011329125B2 (en) | 2010-11-15 | 2015-07-30 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CA2824805A1 (en) | 2011-01-14 | 2012-07-19 | Five Prime Therapeutics, Inc. | Il-27 antagonists for treating inflammatory diseases |
| EP2780033B1 (de) | 2011-11-14 | 2019-05-08 | Five Prime Therapeutics, Inc. | Eine fgfr1 extrazelluläre domäne zur behandlung von krebs mit einer fgfr1 gen vervielfältigung |
| NZ626742A (en) | 2012-02-22 | 2016-06-24 | Alethia Biotherapeutics Inc | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法 |
| EP3884949A1 (de) | 2012-06-08 | 2021-09-29 | Translate Bio, Inc. | Pulmonale verabreichung von mrns an nicht pulmonale zielzellen |
| EP2890398A4 (de) | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | Verfahren zur behandlung von erkrankungen mit antikörpern zur bindung des koloniestimulationsfaktor-1-rezeptors (csf1r) |
| ES2968649T3 (es) | 2012-12-07 | 2024-05-13 | Translate Bio Inc | Nanopartículas lipídicas para la administración de ARNm en los pulmones |
| EP3431592A1 (de) | 2013-03-14 | 2019-01-23 | Translate Bio, Inc. | Therapeutische mrna-zusammensetzungen und verwendung zur behandlung von krankheiten und störungen |
| CA2915665C (en) | 2013-08-01 | 2020-07-28 | Five Prime Therapeutics, Inc. | Afucosylated anti-fgfr2iiib antibodies |
| EP3157957A1 (de) | 2014-06-23 | 2017-04-26 | Five Prime Therapeutics, Inc. | Verfahren zur behandlung von erkrankungen mit antikörpern zur bindung des koloniestimulationsfaktor-1-rezeptors (csf1r) |
| ES2851390T3 (es) | 2014-10-29 | 2021-09-06 | Five Prime Therapeutics Inc | Terapia de combinación para el cáncer |
| JP6797801B2 (ja) | 2014-12-22 | 2020-12-09 | ファイヴ プライム セラピューティクス インク | Ｐｖｎｓを治療するための抗ｃｓｆ１ｒ抗体 |
| RS60614B1 (sr) | 2015-03-23 | 2020-08-31 | Jounce Therapeutics Inc | Antitela za icos |
| JP6971850B2 (ja) | 2015-04-13 | 2021-11-24 | ファイヴ プライム セラピューティクス インク | がんの併用療法 |
| CA2998208A1 (en) | 2015-10-22 | 2017-04-27 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| US10799559B2 (en) | 2016-04-25 | 2020-10-13 | Five Prime Therapeutics, Inc. | NOPE for treatment of pathological muscle loss and weakness |
| MX2019004834A (es) | 2016-11-02 | 2019-06-20 | Jounce Therapeutics Inc | Anticuerpos de pd-1 y usos de estos. |
| CN109906030B (zh) | 2016-11-04 | 2022-03-18 | 安健基因公司 | 用于产生仅重链抗体的经基因修饰的非人动物和方法 |
| JP2020504756A (ja) * | 2016-12-29 | 2020-02-13 | ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | タンパク質薬物のｉｎ ｖｉｖｏ半減期延長のためのキニノーゲン−１由来ペプチド |
| CA3057687A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| WO2018187191A1 (en) | 2017-04-03 | 2018-10-11 | Jounce Therapeutics, Inc | Compositions and methods for the treatment of cancer |
| EP3634988A4 (de) | 2017-06-06 | 2021-02-24 | Kindred Biosciences, Inc. | Erythropoietin und analoge zur verwendung in der veterinärmedizin |
| TWI833724B (zh) | 2017-12-22 | 2024-03-01 | 美商永斯醫療股份有限公司 | 抗ｌｉｌｒｂ２抗體 |
| EP3820904A2 (de) | 2018-07-09 | 2021-05-19 | Five Prime Therapeutics, Inc. | An ilt4 bindende antikörper |
| CN113613727A (zh) * | 2019-01-11 | 2021-11-05 | 嘉立医疗科技(广州)有限公司 | 多特异性前趋化因子治疗蛋白（park）及其制备和使用方法 |
| WO2021178001A1 (en) * | 2020-03-05 | 2021-09-10 | Curie Co. Inc. | Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins |
| AU2021219668A1 (en) | 2020-02-14 | 2022-08-25 | Gilead Sciences, Inc. | Antibodies and fusion proteins that bind to CCR8 and uses thereof |
| KR20230077722A (ko) | 2020-08-10 | 2023-06-01 | 지브이20 테라퓨틱스 엘엘씨 | Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
| WO2023235699A1 (en) | 2022-05-31 | 2023-12-07 | Jounce Therapeutics, Inc. | Antibodies to lilrb4 and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712114A (en) * | 1995-06-06 | 1998-01-27 | Basf Aktiengesellschaft | Compositions for expression of proteins in host cells using a preprocollagen signal sequence |
| EP1105508B1 (de) * | 1998-08-17 | 2002-09-04 | Europäisches Laboratorium Für Molekularbiologie (Embl) | Verfahren zur reinigung von biomolekül- oder proteinkomplexen |
| WO2005082934A2 (en) * | 2004-02-20 | 2005-09-09 | Five Prime Therapeutics, Inc. | Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use |
| JP5435865B2 (ja) * | 2004-07-22 | 2014-03-05 | ファイブ プライム セラピューティクス， インコーポレイテッド | 疾患処置におけるｍｇｄ−ｃｓｆのための組成物およびその使用方法 |
-
2006
- 2006-01-27 AT AT06719694T patent/ATE454455T1/de not_active IP Right Cessation
- 2006-01-27 WO PCT/US2006/002951 patent/WO2006081430A2/en active Application Filing
- 2006-01-27 DK DK06719694.9T patent/DK1841874T3/da active
- 2006-01-27 JP JP2007553266A patent/JP2008528033A/ja active Pending
- 2006-01-27 CA CA002589895A patent/CA2589895A1/en not_active Abandoned
- 2006-01-27 US US11/883,065 patent/US20080286834A1/en not_active Abandoned
- 2006-01-27 DE DE602006011574T patent/DE602006011574D1/de active Active
- 2006-01-27 EP EP06719694A patent/EP1841874B1/de not_active Not-in-force
- 2006-01-27 AU AU2006207999A patent/AU2006207999A1/en not_active Abandoned
-
2009
- 2009-01-19 JP JP2009009381A patent/JP2009131268A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006011574D1 (de) | 2010-02-25 |
| WO2006081430A9 (en) | 2006-11-30 |
| EP1841874B1 (de) | 2010-01-06 |
| JP2008528033A (ja) | 2008-07-31 |
| US20080286834A1 (en) | 2008-11-20 |
| DK1841874T3 (da) | 2010-05-17 |
| EP1841874A2 (de) | 2007-10-10 |
| WO2006081430A2 (en) | 2006-08-03 |
| JP2009131268A (ja) | 2009-06-18 |
| CA2589895A1 (en) | 2006-08-03 |
| AU2006207999A1 (en) | 2006-08-03 |
| WO2006081430A3 (en) | 2007-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE454455T1 (de) | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung | |
| ATE478145T1 (de) | Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren | |
| ATE449109T1 (de) | Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung | |
| DE60137847D1 (de) | Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung | |
| CY1112334T1 (el) | Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων | |
| DK1169442T3 (da) | Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse | |
| ATE448312T1 (de) | Leitsequenzen zur verwendung bei der produktion von proteinen | |
| ATE483810T1 (de) | Entkopplung von dna-propagierung und proteinexpression für phagen-display | |
| WO2006053021A3 (en) | Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby | |
| EP4302824A3 (de) | Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden | |
| ATE408016T1 (de) | Verfahren zur herstellung und sekretion modifizierter peptide | |
| MX2008010389A (es) | Polipeptidos de union quimerica de plantas para reconocimiento molecular universal. | |
| DK1366161T3 (da) | Antagonist anti-PRO842-antistof | |
| DE60117641D1 (de) | Modulierte sekretierte alkalische Phosphatase (SEAP) Reporter Gene und Polypeptide | |
| DK1300417T3 (da) | Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor | |
| DE69926415D1 (de) | Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren | |
| DK1591452T3 (da) | Secernerede og transmembrane polypeptider og nukleinsyrer kodende for samme | |
| DK1621619T3 (da) | Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse | |
| ATE447026T1 (de) | Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure | |
| ATE489463T1 (de) | Polypeptid mit einer delta-5-fettsäure- desaturierungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon. | |
| DE69930422D1 (de) | Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren | |
| DK1241184T3 (da) | Humant synaptogyrin-lignende protein og nukleinsyrer kodende for dette | |
| DK1241183T3 (da) | Humant HCAR-agtig protein og nucleinsyrer kodende derfor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |